Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | TRIP13 | Q15645 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187244 | 1.00 | ATM (0.58) | ATMALDH1A1TRIP13SMN1; SMN2MEN1 | |
| SCHEMBL26083602 | 0.84 | ALDH1A1 (0.50) | ATMALDH1A1TRIP13SMN1; SMN2MEN1 | |
| SCHEMBL26109334 | 0.84 | ALDH1A1 (0.50) | ATMALDH1A1TRIP13SMN1; SMN2MEN1 | |
| SCHEMBL3192393 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3190222 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3190214 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3192400 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3190209 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13483329 | 0.84 | TSHR (0.42) | ATMALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3186419 | 0.82 | ALDH1A1 (0.62) | ATMALDH1A1TRIP13MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ATM 1135/4885ALDH1A1 3191/4885TRIP13 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.